Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 14/20 | 0.69 |
| ▸ | EDNRA | P25101 | 11/20 | 0.55 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8547308 | 0.93 | EDNRB (0.59) | EDNRBEDNRASERPINE1 | |
| SCHEMBL8548814 | 0.92 | EDNRB (0.57) | EDNRBEDNRASERPINE1 | |
| SCHEMBL8551372 | 0.91 | EDNRB (0.57) | EDNRBEDNRAPLA2G2A | |
| SCHEMBL8551968 | 0.90 | EDNRB (0.55) | EDNRBEDNRAKMT2APLA2G2A | |
| SCHEMBL8545779 | 0.90 | EDNRB (0.55) | EDNRBEDNRASERPINE1 | |
| SCHEMBL8624241 | 0.88 | EDNRB (0.52) | EDNRBEDNRA | |
| SCHEMBL8551303 | 0.87 | EDNRB (0.59) | EDNRBEDNRASERPINE1 | |
| SCHEMBL8548173 | 0.87 | EDNRB (0.52) | EDNRBEDNRAKMT2APLA2G2A | |
| SCHEMBL8553567 | 0.86 | EDNRB (0.67) | EDNRBEDNRASERPINE1KMT2A | |
| SCHEMBL8549579 | 0.86 | EDNRB (0.68) | EDNRBEDNRASERPINE1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0863898-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997019077-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1997-05-29 | — | — | WO | disclosed |